Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 antibody prevalence by industry, workplace characteristics, and workplace infection prevention and control measures, North Carolina, 2021 to 2022

View ORCID ProfileCarolyn Gigot, View ORCID ProfileNora Pisanic, Kristoffer Spicer, Meghan F. Davis, Kate Kruczynski, Magdielis Gregory Rivera, Kirsten Koehler, D. J. Hall Jr., Devon J. Hall, View ORCID ProfileChristopher D. Heaney
doi: https://doi.org/10.1101/2024.03.06.24303821
Carolyn Gigot
aDepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carolyn Gigot
  • For correspondence: cgigot1{at}jhu.edu cheaney1{at}jhu.edu
Nora Pisanic
aDepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nora Pisanic
Kristoffer Spicer
aDepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meghan F. Davis
aDepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
bJohns Hopkins P.O.E. Total Worker Health(R) Center in Mental Health, Baltimore, Maryland, USA
cDivision of Infectious Diseases and Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kate Kruczynski
aDepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magdielis Gregory Rivera
aDepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirsten Koehler
aDepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. J. Hall Jr.
dRural Empowerment Association for Community Help, Warsaw, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Devon J. Hall
dRural Empowerment Association for Community Help, Warsaw, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher D. Heaney
aDepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
eDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,Maryland, USA
fDepartment of International Health Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
gCommunity Science and Innovation for Environmental Justice Initiative, Center for a Livable Future, Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher D. Heaney
  • For correspondence: cgigot1{at}jhu.edu cheaney1{at}jhu.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background The COVID-19 pandemic has disproportionately affected workers in certain industries and occupations, and the workplace can be a high risk setting for SARS-CoV-2 transmission. In this study, we measured SARS-CoV-2 antibody prevalence and identified work-related risk factors in a population primarily working at industrial livestock operations.

Methods We used a multiplex salivary SARS-CoV-2 IgG antibody assay to determine infection-induced antibody prevalence among 236 adult (≥18 years) North Carolina residents between February 2021 and August 2022. We used the National Institute for Occupational Safety and Health Industry and Occupation Computerized Coding System (NIOCCS) to classify employed participants’ industry and compared infection-induced IgG prevalence by participant industry and with the North Carolina general population. We also combined antibody results with reported SARS-CoV-2 molecular test positivity and vaccination history to identify evidence of prior infection. We used logistic regression to estimate odds ratios of prior infection by potential work-related risk factors, adjusting for industry and date.

Results Most participants (55%) were infection-induced IgG positive, including 71% of animal slaughtering and processing industry workers, which is 1.5 to 4.3 times higher compared to the North Carolina general population, as well as higher than molecularly-confirmed cases and the only other serology study we identified of animal slaughtering and processing workers. Considering questionnaire results in addition to antibodies, the proportion of participants with evidence of prior infection increased slightly, to 61%, including 75% of animal slaughtering and processing workers. Participants with more than 1000 compared to 10 or fewer coworkers at their jobsite had higher odds of prior infection (adjusted odds ratio [aOR] 4.5, 95% confidence interval [CI] 1.0 to 21.0).

Conclusions This study contributes evidence of the severe and disproportionate impacts of COVID-19 on animal processing and essential workers and workers in large congregate settings. We also demonstrate the utility of combining non-invasive biomarker and questionnaire data for the study of workplace exposures.

Conflict of Interest The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

What’s important about this paper High numbers of COVID-19 outbreaks, cases, and deaths have been reported among livestock industry workers, including Black and Hispanic workers, in the United States. Little is known about SARS-CoV-2 infection as measured by antibody prevalence in this setting. Antibody-based estimates of SARS-CoV-2 infection can capture cases missed by SARS-CoV-2 molecular testing, which is important given limitations in worker access to molecular diagnostic testing. We observed high SARS-CoV-2 infection-induced IgG prevalence in animal slaughtering and processing industry workers (71%) between February 2021 and August 2022, which is 1.5 to 4.3 times higher compared to the North Carolina general population, as well as higher than molecularly-confirmed cases and the only serology study we identified of animal slaughtering and processing workers. We also found higher odds of SARS-CoV-2 infection among participants at worksites with larger compared to smaller numbers of employees.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by an anonymous gift, the JHU COVID-19 Research and Response Program, the FIA Foundation, NIAID R21 AI139784, and a NIOSH POE Total Worker Health Center (U19 OH012297) pilot project grant. C.G., K. Koehler, and C.D.H. were supported by NIOSH ERC (T42 OH0008428). M.F.D and K. Koehler were also supported by the NIOSH POE Center (U19 OH012297). N.P., K. Kruczynski, M.G.R., K.S., and C.D.H. were supported by an anonymous gift, the JHU COVID-19 Research and Response Program, and the FIA Foundation. C.D.H was additionally supported by NIEHS (R01ES026973), NIAID (R43AI141265, R01AI130066, R01ES026973), and NIH (U24OD023382).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board (IRB) of the Johns Hopkins Bloomberg School of Public Health gave ethical approval for this study (IRB00014420).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data availability

Deidentified data and code can be requested by email to the corresponding authors (cgigot1{at}jhu.edu and cheaney1{at}jhu.edu).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 08, 2024.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 antibody prevalence by industry, workplace characteristics, and workplace infection prevention and control measures, North Carolina, 2021 to 2022
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 antibody prevalence by industry, workplace characteristics, and workplace infection prevention and control measures, North Carolina, 2021 to 2022
Carolyn Gigot, Nora Pisanic, Kristoffer Spicer, Meghan F. Davis, Kate Kruczynski, Magdielis Gregory Rivera, Kirsten Koehler, D. J. Hall Jr., Devon J. Hall, Christopher D. Heaney
medRxiv 2024.03.06.24303821; doi: https://doi.org/10.1101/2024.03.06.24303821
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 antibody prevalence by industry, workplace characteristics, and workplace infection prevention and control measures, North Carolina, 2021 to 2022
Carolyn Gigot, Nora Pisanic, Kristoffer Spicer, Meghan F. Davis, Kate Kruczynski, Magdielis Gregory Rivera, Kirsten Koehler, D. J. Hall Jr., Devon J. Hall, Christopher D. Heaney
medRxiv 2024.03.06.24303821; doi: https://doi.org/10.1101/2024.03.06.24303821

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Occupational and Environmental Health
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)